[Second cancers associated with the cancer treatment and their possible control].
Second cancers induced by both alkylating agents and topoisomerase II inhibitors are reviewed with special reference to their distinct clinical features, incidences observed in the population at risk, cumulative risks, underlying molecular-genetic abnormalities, and also some detoxifying enzyme polymorphisms recently identified. Finally, it was discussed whether we can control these devastating diseases in the future.
Abe
Tatsuo
T
Department of Medicine, Keihoku Hospital.
Nomura
Kenichi
K
D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects*; D006801:Humans; D007938:Leukemia / Q000139:chemically induced*; D016609:Neoplasms, Second Primary / Q000139:chemically induced*; D059005:Topoisomerase II Inhibitors
D018906:Antineoplastic Agents, Alkylating; D059005:Topoisomerase II Inhibitors